Management of Chronic Myeloid Leukemia Patients During Pregnancy (Analysis of Literature and Practical Recommendations)

Background. The tyrosine kinase inhibitors (TKI) era is marked by a long-term favorable prognosis of chronic myeloid leukemia (CML). In this context CML patients of reproductive age are faced with major issues of family planning with due regard to the risk of TKI treatment interruption during pregnancy. Additionally, TKI impact is another potential risk to the fetus.

Aim. To develop differentiated approach to CML treatment during pregnancy.

Materials & Methods. Analysis includes literature data and clinical experience based on 166 pregnancies of 120 CML patients from CML Pregnancy Registry.

Results. Pregnancy planning is recommended after achieving stable and deep molecular response (with BCR-ABL > 0.01 %, IS) within the period of at least 2 years. At conception TKI therapy does not have to be interrupted. However, early pregnancy detection and TKI treatment interruption after pregnancy confirmation are of vital importance due to teratogenic risks. Furthermore, no TKI may be administered during organogenetic period, i.e. up to the 15^th week of gestation. In the absence or loss of complete hematologic response and growth of BCR-ABL > 1 % after the 15^th week of gestation imatinib or nilotinib administration is justified in the interest of pregnant patients taking into account limited transfer of these drugs through placenta. In the absence of complete hematologic response before the 15^th week of gestation interferon-α can be administered. With BCR-ABL < 1 % patients can be either followed-up without therapy or they can receive interferon-α throughout pregnancy. Dasatinib, bosutinib, and other TKI are contraindicated at any stage of pregnancy. There are no special recommendations for childbirth, delivery is to be adapted to obstetric conditions. Breast feeding is not recommended because of the lack of practical evidence for its safety.

Conclusion. A regular molecular monitoring of BCR-ABL and hematologic status is indispensable, health condition of fetus should be continuously monitored as well. CML patient management should be conducted by cooperating hematologists and gynecologists.

• Ekaterina Yur’evna Chelysheva National Medical Hematology Research Center, 4a Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 ; ФГБУ «НМИЦ гематологии» Минздрава России, Новый Зыковский пр-д, д. 4а, Москва, Российская Федерация, 125167
• A.G. Turkina National Medical Hematology Research Center, 4a Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 ; ФГБУ «НМИЦ гематологии» Минздрава России, Новый Зыковский пр-д, д. 4а, Москва, Российская Федерация, 125167
• E.S. Polushkina VI Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, 4 Akademika Oparina str., Moscow, Russian Federation, 117997 ; ФГБУ «НМИЦ акушерства, гинекологии и перинатологии им. В.И. Кулакова» Минздрава России, ул. Академика Опарина, д. 4, Москва, Российская Федерация, 117997
• M.A. Vinogradova VI Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, 4 Akademika Oparina str., Moscow, Russian Federation, 117997 ; ФГБУ «НМИЦ акушерства, гинекологии и перинатологии им. В.И. Кулакова» Минздрава России, ул. Академика Опарина, д. 4, Москва, Российская Федерация, 117997
• R.G. Shmakov VI Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, 4 Akademika Oparina str., Moscow, Russian Federation, 117997 ; ФГБУ «НМИЦ акушерства, гинекологии и перинатологии им. В.И. Кулакова» Минздрава России, ул. Академика Опарина, д. 4, Москва, Российская Федерация, 117997

1. Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–27. doi: 10.1056/NEJMoa1609324. DOI: https://doi.org/10.1056/NEJMoa1609324
2. Shukhov O, Chelysheva E, Gusarova G, et al. Imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase: current incidence of cytogenetic remission and a very long-term an intention-to-treat analysis. Haematologica. 2015;100(Suppl 1):437.
3. Куликов С.М., Виноградова О.Ю., Челышева Е.Ю. и др. Заболеваемость хроническим миелолейкозом в 6 регионах России по данным популяционного исследования 2009–2012 гг. Терапевтический архив. 2014;86(7):24–30.
4. [Kulikov SM, Vinogradova OYu, Chelysheva EYu, et al. Incidence of chronic myeloid leukemia in 6 regions of Russia according to the data of the 2009–2012 population-based study. Terapevticheskii arkhiv. 2014;86(7):24–30. (In Russ)]
5. Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia. 2015;29(6):1336–43. doi: 10.1038/leu.2015.73. DOI: https://doi.org/10.1038/leu.2015.73
6. Carlier P, Bernard N, Lagarce L, et al. Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia: reports collected by the French network pharmacovigilance centers. Arch Gynecol Obstet. 2017;295(2):269–71. doi: 10.1007/s00404-016-4262-z. DOI: https://doi.org/10.1007/s00404-016-4262-z
7. Abruzzese E, Trawinska MM, de Fabritiis P, et al. Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis. 2014;6(1):2014028. doi: 10.4084/MJHID.2014.028. DOI: https://doi.org/10.4084/mjhid.2014.028
8. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Pregnancy outcomes in patients treated with bosutinib. Blood. 2018;132:1729, abstract. DOI: https://doi.org/10.1182/blood-2018-99-110547
9. Palani R, Milojkovic D, Apperley JF. Managing pregnancy in chronic myeloid leukemia. Ann Hematol. 2015;94(Suppl 2):S167–76. doi: 10.1007/s00277-015-2317-z. DOI: https://doi.org/10.1007/s00277-015-2317-z
10. Bhandari A, Rolen K, Shah BK. Management of chronic myelogenous leukemia in pregnancy. Anticancer Res. 2015;35(1):1–11.
11. Abruzzese E, Trawinska MM, de Fabritiis P, et al. Management of pregnant chronic myeloid leukemia patients. Expert Rev Hematol. 2016;9(8):781–91. doi: 10.1080/17474086.2016.1205479. DOI: https://doi.org/10.1080/17474086.2016.1205479
12. Челышева Е.Ю., Туркина А.Г. Протокол лечения хронического миелолейкоза во время беременности. В кн.: Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Под ред. В.Г. Савченко. М.: Практика, 2018. Т. 2. С. 927–49.
13. [Chelysheva EYu, Turkina AG. Protocol of chronic myeloid leukemia treatment during pregnancy. In: Savchenko VG, ed. Algoritmy diagnostiki i protokoly lecheniya zabolevanii sistemy krovi. (Diagnostic algorithms and treatment protocols for blood system diseases.) Moscow: Praktika Publ.; 2018. Vol. 2. pp. 927–49. (In Russ)]
14. Челышева Е.Ю., Туркина А.Г., Чабаева Ю.А. и др. Регистр случаев беременности при хроническом миелолейкозе: клинико-демографическая характеристика пациентов. Гематология и трансфузиология. 2016;61(1-S1):79.
15. [Chelysheva EYu, Turkina AG, Chabaeva YuA, et al. Registry of pregnancy cases in chronic myeloid leukemia: clinical and demographic characteristics of patients. Gematologiya i transfuziologiya, 2016;61(1-S1):79. (In Russ)]
16. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84. doi: 10.1182/blood-2013-05-501569. DOI: https://doi.org/10.1182/blood-2013-05-501569
17. Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. 2016;128(1):17–23. doi: 10.1182/blood-2016-01-694265. DOI: https://doi.org/10.1182/blood-2016-01-694265
18. Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv261. doi: 10.1093/annonc/mdy159. DOI: https://doi.org/10.1093/annonc/mdy159
19. National Comprehensive Cancer Network. Chronic myeloid leukemia (Version 4.2018). Available from: https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. (accessed 8.01.2019).
20. Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol. 2003;40(2 Suppl 2):21–5. doi: 10.1053/shem.2003.50038. DOI: https://doi.org/10.1016/S0037-1963(03)70016-X
21. Cortes JE, Abruzzese E, Chelysheva E, et al. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015;90(12):1111–5. doi: 10.1002/ajh.24186. DOI: https://doi.org/10.1002/ajh.24186
22. Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111(12):5505–8. doi: 10.1182/blood-2007-10-114900. DOI: https://doi.org/10.1182/blood-2007-10-114900
23. Berveiller P, Andreoli A, Mir O, et al. A dramatic fetal outcome following transplacental transfer of dasatinib. Anti-Cancer Drugs. 2012;23(7):754–7. doi: 10.1097/CAD.0b013e328352a8fe. DOI: https://doi.org/10.1097/CAD.0b013e328352a8fe
24. Polin RA, Fox WW, Abman SH. Fetal and Neonatal Physiology. 4th edition; 2011. 2208 p. [Internet] Available from: http://readli.net/fetal-and-neonatal-physiology. (accessed 8.01.2019).
25. Abruzzese E, Scortechini AR, Gugliotta G, et al. Gimema Registry of conception/pregnancy in adult patients diagnosed with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs). Blood. 2014;124:1806, abstract. DOI: https://doi.org/10.1182/blood.V124.21.1806.1806
26. Chelysheva E, Galaiko MV, Kolosheinova TI, et al. Outcomes of pregnancy and therapeutic approaches in chronic myeloid leukemia during pregnancy. Hematologica. 2014;99(Suppl 1):336–7.
27. Jovelet C, Seck A, Mir O, et al. Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model. Ann Oncol. 2015;26(7):1500–4. doi: 10.1093/annonc/mdv172. DOI: https://doi.org/10.1093/annonc/mdv172
28. Chelysheva E, Turkina A, Polushkina E, et al. Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. Leuk Lymphoma. 2018;59(3):733–8. doi: 10.1080/10428194.2017.1347929. DOI: https://doi.org/10.1080/10428194.2017.1347929
29. Russel MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentration in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol. 2007;27(4):241–3. doi: 10.1038/sj.jp.7211665. DOI: https://doi.org/10.1038/sj.jp.7211665
30. Cole S, Kantarjian H, Ault P, et al. Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature. Clin Lymph Myel. 2009;9(4):324–7. doi: 10.3816/CLM.2009.n.064. DOI: https://doi.org/10.3816/CLM.2009.n.064
31. Iqbal J, Ali Z, Khan AU, et al. Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country. Leuk Lymphoma. 2014;55(9):2109–13. doi: 10.3109/10428194.2013.866662. DOI: https://doi.org/10.3109/10428194.2013.866662
32. Alizadeh H, Jaafar H, Rajnics P, et al. Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre. Leuk Res. 2015;39(1):47–51. doi: 10.1016/j.leukres.2014.10.002. DOI: https://doi.org/10.1016/j.leukres.2014.10.002
33. Saussele S, Richter J, Hochhaus A, et al. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30(8):1638–47. doi: 10.1038/leu.2016.115. DOI: https://doi.org/10.1038/leu.2016.115
34. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–35. doi: 10.1016/S1470-2045(10)70233-3. DOI: https://doi.org/10.1016/S1470-2045(10)70233-3
35. Rea D, Nicolini F, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI Study. Blood. 2017;129(7):846–54. doi: 10.1182/blood-2016-09-742205. DOI: https://doi.org/10.1182/blood-2016-09-742205
36. Saussele S, Richter J, Guilhot J, et al Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747–7. doi: 10.1016/S1470-2045(18)30192-X. DOI: https://doi.org/10.1016/S1470-2045(18)30192-X
37. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424–30. doi: 10.1200/JCO.2012.48.5797. DOI: https://doi.org/10.1200/JCO.2012.48.5797
38. Chelysheva E, Apperley J, Abruzzese E, et al. Kinetics of the leukemic clone in patients with chronic myeloid leukemia during pregnancy. 2018;132(Suppl 1):4254, abstract. DOI: https://doi.org/10.1182/blood-2018-99-115984
39. Burchert A, Muller MC, Kostrewa P, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol. 2010;28(8):1429–35. doi: 10.1200/JCO.2009.25.5075. DOI: https://doi.org/10.1200/JCO.2009.25.5075
40. Law AD, Kim DHD, Lipton JH. Pregnancy: part of life in chronic myelogenous leukemia. Leuk Lymphoma. 2017;58(2):280–7. doi: 10.1080/10428194.2016.1201571. DOI: https://doi.org/10.1080/10428194.2016.1201571
41. Patel M, Dukes IA, Hull JC. Use of hydroxyurea in chronic myeloid leukemia during pregnancy; a case report. Am J Obstet Gynecol. 1991;165(3):565–6. doi: 10.1016/0002-9378(91)90285-y. DOI: https://doi.org/10.1016/0002-9378(91)90285-Y
42. Tretian G, Tchernia G, Papiernik E, et al. Hydroxyurea and pregnancy. Am J Obstet Gynecol. 1992;166(6):1868. doi: 10.1016/0002-9378(92)91590-7. DOI: https://doi.org/10.1016/0002-9378(92)91590-7
43. Assi R, Kantarjian HM, Keating MJ, et al. Management of chronic myeloid leukemia (CML) during pregnancy among patients (pts) treated with a tyrosine kinase inhibitor (TKI): a single-center experience. Blood. 2017;130:2881, abstract.
44. Ali R, Ozkalemkas F, Kimya Y, et al. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet. 2009;280(2):169–75. doi: 10.1007/s00404-008-0861-7. DOI: https://doi.org/10.1007/s00404-008-0861-7
45. Chelysheva E, Aleshin S, Polushkina E, et al. Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and literature review. Mediterr J Hematol Infect Dis. 2018;10(1):2018027. doi: 10.4084/MJHID.2018.027. DOI: https://doi.org/10.4084/mjhid.2018.027
46. Chelysheva E, Turkina A, Polushkina E, et al. Results of treatment of patients with chronic myeloid leukemia and pregnancy in accordance with the leukemic burden and term of pregnancy (the LET scheme). EHA Learning Center. 2018. Abstract PF375. Available from: https://learningcenter.ehaweb.org/eha/2018/stockholm/214848/ekaterina.chelysheva.results.of.treatment.of.patients.with.chronic.myeloid.html?f=menu=6*ce_id=1346*ot_id=19052*media=3*marker=167 (accessed 8.01.2019).
47. Chelysheva E, Turkina A, Polushkina E, et al. Treatment of patients with chronic myeloid leukemia during pregnancy according to scheme considering the leukemic burden and term of pregnancy (the LRT scheme). Clin Lymph Myel Leuk. 2018;18:S227–8. doi: 10.1016/j.clml.2018.07.102. DOI: https://doi.org/10.1016/j.clml.2018.07.102
48. Chelysheva E, Abruzzese E, Rea D, et al. Chronic myeloid leukemia diagnosed during pregnancy: therapy, outcomes and follow-up. 2018;132(Suppl 1):4255, abstract. DOI: https://doi.org/10.1182/blood-2018-99-115983
49. Abruzzese E, de Fabritiis P, Trawinska MM, et al. Back to the future: Treatment-free remission and pregnancy in chronic myeloid leukemia. Eur J Haematol. 2018;102(2):197–9. doi: 10.1111/ejh.13192. DOI: https://doi.org/10.1111/ejh.13192